Effect of thalidomide in hepatocellular carcinoma: Assessment with power Doppler US and analysis of circulating angiogenic factors

Radiology

Volumn 235, Issue 2, 2005, Pages 509-516

  Hsu, Chiun ^a,b   Chen, Chiung Nien ^a   Chen, Li Tzong ^c,d   Wu, Chen Yao ^a   Hsieh, Fon Jou ^a   Cheng, Ann Lii ^a,b,c  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^d KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; ANGIOGENIC FACTOR; BASIC FIBROBLAST GROWTH FACTOR; PLACENTAL GROWTH FACTOR; THALIDOMIDE; VASCULOTROPIN;

AGED; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DOPPLER FLOWMETRY; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FISHER EXACT TEST; HUMAN; INFORMED CONSENT; LIVER CELL CARCINOMA; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANK SUM TEST; TUMOR GROWTH; TUMOR VASCULARIZATION; WORLD HEALTH ORGANIZATION;

ADULT; AGED; AGED, 80 AND OVER; ALPHA-FETOPROTEINS; ANGIOGENESIS INDUCING AGENTS; ANGIOGENESIS INHIBITORS; CARCINOMA, HEPATOCELLULAR; FEMALE; FIBROBLAST GROWTH FACTOR 2; FOLLOW-UP STUDIES; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; NEOVASCULARIZATION, PATHOLOGIC; PREGNANCY PROTEINS; PROSPECTIVE STUDIES; THALIDOMIDE; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; ULTRASONOGRAPHY, DOPPLER, COLOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 17644376932     PISSN: 00338419     EISSN: None     Source Type: Journal    
DOI: 10.1148/radiol.2352040271     Document Type: Article

References (48)

1. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285:1182-1186.
2. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86:353-364.
3. Arap W, Pasqualini R, Ruoslahti E. Chemotherapy targeted to tumor vasculature. Curr Opin Oncol 1998; 10:560-565.
4. Boehm T, Folkman J, Browder T, O'Reilly MS. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 1997; 390:404-407.
5. El-Assal ON, Yamanoi A, Soda Y, et al. Clinical significance of microvessel density and vascular endothelial growth factor expression in hepatocellular carcinoma and surrounding liver: possible involvement of vascular endothelial growth factor in the angiogenesis of cirrhotic liver. Hepatology 1998; 27:1554-1562.
6. Poon RT, Ng IO, Lau C, et al. Serum vascular endothelial growth factor predicts venous invasion in hepatocellular carcinoma: a prospective study. Ann Surg 2001; 233:227-235.
7. D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A 1994; 91:4082-4085.
8. Kenyon BM, Browne F, D'Amato R. Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization. Exp Eye Res 1997; 64:971-978.
9. Singhal S, Mehta J, Desikan R, et al. Anti-tumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999; 341:1565-1571.
10. Little RF, Wyvill KM, Pluda JM, et al. Activity of thalidomide in AIDS-related Kaposi's sarcoma. J Clin Oncol 2000; 18: 2593-2602.
11. Hsu C, Chen CN, Chen LT, et al. Low-dose thalidomide treatment for advanced hepatocellular carcinoma. Oncology 2003; 65:242-249.
12. Chen CN, Cheng YM, Liang JT, et al. Color Doppler vascular index can predict distant metastasis and survival in colon cancer patients. Cancer Res 2000; 60: 2892-2897.
13. Chen CN, Cheng YM, Lin MT, Hsieh FJ, Lee PH, Chang KJ. Association of color Doppler vascularity index and microvessel density with survival in patients with gastric cancer. Ann Surg 2002; 235:512-518.
14. Wu CC, Lee CN, Chen TM, et al. Incremental angiogenesis assessed by color Doppler ultrasound in the tumorigenesis of ovarian neoplasm. Cancer 1994; 73: 1251-1256.
15. Cheng WF, Lee CN, Chu JS, et al. Vascular index as a novel parameter for the in vivo assessment of angiogenesis in patients with cervical carcinoma. Cancer 1999; 85:651-657.
16. Choi BI, Kim TK, Han JK, Chung JW, Park JH, Han MC. Power versus conventional color Doppler sonography: comparison in the depiction of vasculature in liver tumors. Radiology 1996; 200:55-58.
17. Lencioni R, Pinto F, Armillotta N, Bartolozzi C. Assessment of tumor vascularity in hepatocellular carcinoma: comparison of power Doppler US and color Doppler US. Radiology 1996; 201:353-358.
18. Poon RT, Fan ST, Wong J. Clinical implications of circulating angiogenic factors in cancer patients. J Clin Oncol 2001; 19:1207-1225.
19. Li XM, Tang ZY, Qin LX, et al. Serum vascular endothelial growth factor is a predictor of metastasis in hepatocellular carcinoma. J Exp Clin Cancer Res 1999; 18:511-517.
20. Hsu PI, Chow NH, Lai KH, et al. Implication of serum basic fibroblastic growth factor levels in chronic liver diseases and hepatocellular carcinoma. Anticancer Res 1997; 17:2803-2810.
21. Carmeliet P, Moons L, Luttun A, et al. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med 2001; 7:575-583.
22. Liaw YF, Tai DI, Chen TJ, Chu CM, Huang MJ. Alpha-fetoprotein changes in the course of chronic hepatitis: relation to bridging hepatic necrosis and hepatocellular carcinoma. Liver 1986; 6:133-137.
23. Okuda K. Early detection of hepatocellular carcinoma. Hepatology 1986; 6:729-738.
24. American Joint Committee on Cancer. Manual for staging of cancer. 4th ed. Philadelphia, Pa: Lippincott, 1992.
25. The Cancer of the Liver Italian Program (CLIP) investigators. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients. Hepatology 1998; 28:751-755.
26. Pugh RNH, Murray-Lyon IM, Dawson J-L, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973; 60:646-649.
27. Cancer Therapy Evaluation Program. Common toxicity criteria, version 2.0. National Cancer Institute Web site. http://ctep.cancer.gov/reporting/CTC-3. html. Published March 1998. Accessed February 22, 2005.
28. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47:207-214.
29. Schag CC, Heinrich RL, Ganz PA. Karnofsky performance status revisited: reliability, validity, and guidelines. J Clin Oncol 1984; 2:187-193.
30. Padhani AR, Neeman M. Challenges for imaging angiogenesis. Br J Radiol 2001; 74:886-890.
31. Choyke PL, Knopp MV, Libutti SK. Special techniques for imaging blood flow to tumors. Cancer J 2002; 8:109-118.
32. Donnelly EF, Geng L, Wojcicki WE, Fleischer AC, Hallahan DE. Quantified power Doppler US of tumor blood flow correlates with microscopic quantification of tumor blood vessels. Radiology 2001; 219:166-170.
33. Goertz DE, Yu JL, Kerbel RS, Burns PN, Foster FS. High-frequency Doppler ultrasound monitors the effects of antivascular therapy on tumor blood flow. Cancer Res 2002; 62:6371-6375.
34. Gee MS, Saunders HM, Lee JC, et al. Doppler ultrasound imaging detects changes in tumor perfusion during antivascular therapy associated with vascular anatomic alterations. Cancer Res 2001; 61:2974-2982.
35. Rubin JM, Bude RO, Carson PL, Bree RL, Adler RS. Power Doppler US: a potentially useful alternative to mean-frequency-based color Doppler US. Radiology 1994; 190:853-856.
36. Bartolozzi C, Lencioni R, Ricci P, Paolicchi A, Rossi P, Passariello R. Hepatocellular carcinoma treatment with percutaneous ethanol injection: evaluation with contrast-enhanced color Doppler US. Radiology 1998; 209:387-393.
37. Vilana R, Llovet JM, Bianchi L, et al. Contrast-enhanced power Doppler sonography and helical computed tomography for assessment of vascularity of small hepatocellular carcinomas before and after percutaneous ablation. J Clin Ultrasound 2003; 31:119-128.
38. Choi BI, Kim TK, Han JK, Kim AY, Seong CK, Park SJ. Vascularity of hepatocellular carcinoma: assessment with contrast-enhanced second harmonic versus conventional power Doppler US. Radiology 2000; 214:381-386.
39. Lencioni R, Cioni D, Bartolozzi C. Tissue harmonic and contrast-specific imaging: back to gray scale in ultrasound. Eur Radiol 2002; 12:151-165.
40. Hlatky L, Hahnfeldt P, Folkman J. Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn't tell us. J Natl Cancer Inst 2002; 94:883-893.
41. Moreira AL, Sampaio EP, Zmuidzinas A, et al. Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J Exp Med 1993; 177:1675-1680.
42. Haslett PA, Corral LG, Albert M, et al. Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset. J Exp Med 1998; 187:1885-1892.
43. Bertolini F, Mingrone W, Alietti A, et al. Thalidomide in multiple myeloma, myelodysplastic syndromes and histiocytosis: analysis of clinical results and of surrogate angiogenesis markers. Ann Oncol 2001; 12:987-990.
44. Neben K, Moehler T, Kraemer A, et al. Response to thalidomide in progressive multiple myeloma is not mediated by inhibition of angiogenic cytokine secretion. Br J Haematol 2001; 115:605-608.
45. Pittini V, Teti D, Arrigo C, et al. Thalidomide treatment of relapsed multiple myeloma patients and changes in circulating VEGF and bFGF (letter). Br J Haematol 2002; 119:275.
46. Dmoszynska A, Bojarska-Junak A, Domanski D, et al. Production of proangiogenic cytokines during thalidomide treatment of multiple myeloma. Leuk Lymphoma 2002; 43:401-406.
47. Neben K, Moehler T, Egerer G, et al. High plasma basic fibroblast growth factor concentration is associated with response to thalidomide in progressive multiple myeloma. Clin Cancer Res 2001; 7:2675-2681.
48. Fine HA, Figg WD, Jaeckle K, et al. Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. J Clin Oncol 2000; 18: 708-715.